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or older and were diagnosed as diabetes during July 2008 – June 2011 with 
receiving glucose lowering agent were included. All included patients were 
categorized into thiazolidinedione (TZDs) and non-TZDs groups. PS were 
estimated by conventional and time-specific approaches. In the time-specific 
approach, PS was separately estimated into 3 groups by calendar time. The pair 
t-test was used to compare the PS of both approaches. Patients were matched 
using caliper nearest neighbor matching with no replacement. The multivariate 
Cox proportional hazard model was used to determine the adjusted hazard ratio 
of cardiovascular hospitalizations of TZDs and non-TZDs in matched cohorts. 
RESULTS: A total of 2165 patients were included in this study. Patients were on 
average 58.8 ± 12.7 years of age with 44.5% of male. The average conventional PS 
was 0.198, which was significantly lower than the average time-specific PS of 
0.209.For CVD-related hospitalization, the adjusted hazard ratio (HR) of 
conventional PS-matched cohort was 1.05 (95% confidence interval (CI); 0.38 – 
2.89), while that of time specific PS-matched cohort was 1.12 (95%CI; 0.43 – 2.92). 
CONCLUSIONS: Propensity scores estimated by conventional and time-specific 
approaches were different. The different PS approaches could lead to different 
estimates of treatment effects. 
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PRM1  
THE IMPLICATIONS OF EVALUATING MEDICATION ADHERENCE AT DIFFERENT 
DRUG CLASSIFICATION LEVELS  
Lou Y1, Huang Z2, Wang S2, Taitel M1 
1Walgreen Co., Deerfield, IL, USA, 2Walgreens Co., Deerfield, IL, USA  
OBJECTIVES: Proportion of days covered (PDC) has gained increased popularity 
as a key measure of medication adherence. The Centers for Medicare and 
Medicaid Services (CMS) now uses PDC to measure medication adherence for 
quality improvement in Medicare Part D. PDC can be calculated at various drug 
classification levels such as a particular drug (e.g. metformin, glipizide) or a 
broad therapeutic class (e.g. all oral anti-diabetes drugs). The objective of this 
analysis is to show how PDC calculations at different drug levels can result in 
varied adherence estimates. METHODS: The analysis used a sample of claims 
data for all oral anti-diabetes drugs from a national pharmacy and defined drug 
levels using Medispan’s Generic Product Identifiers (GPI). Three methods were 
used to calculate PDCs. In method 1, PDC was computed for each GPI6, and then 
rolled up to the patient level using weighted averages. In methods 2 and 3, PDC 
was calculated for the entire therapeutic area of oral anti-diabetes drugs. Method 
2 used GPI6, and method 3 used GPI10 to determine the drugs; any medication 
overlaps between different drugs were ignored to avoid double counting and any 
medication overlaps within the same drug were pushed out to make adjustment 
in the days covered. RESULTS: PDC was 0.64 for method 1 and 0.69 for both 
methods 2 and 3. Compared to method 1, PDCs from method 2 and 3 were 5% 
higher (N= 188,121, P-value < 0.0001). Among patients with 1 or more distinct 
GPI6s, the difference was even bigger – PDCs from method 2 and 3 were 10% 
higher (N= 90,064, P-value< 0.0001) than that from method 1 (0.75 vs. 0.65). 
CONCLUSIONS: PDCs at varied drug levels could lead to different medication 
adherence estimates and impact conclusions about medication adherence, 
especially for patients who switch drugs within a drug class or use combination 
therapies.  
 
PRM2  
COMPARISON OF TWO METHODS FOR IDENTIFYING PROBLEMATIC OPIOID USE 
AMONG AN OPIOID-TREATED CHRONIC PAIN POPULATION  
Ruetsch C1, Tkacz J2 
1Health Analytics, Columbia, MD, USA, 2Health Analytics, LLC, Columbia, MD, USA  
OBJECTIVES: In recent years, addiction and problematic use of prescription 
opioid analgesic medications has increased. Using medical and pharmacy claims 
data, the purpose of this study was to compare two methods of characterizing 
problematic opioid use among a commercially insured chronic pain patient 
population. METHODS: A national managed care organization provided medical 
and pharmacy data for individuals with chronic pain and an opioid prescription 
fill during calendar years 2009-2011. Members were placed into one of two 
problematic opioid use groups based on the following criteria: “Doctor Shopping” 
(n = 552), defined as the filling of opioid prescriptions from five or more different 
prescribers within 12 months; and “Rapid Dose Escalation” (n = 741), defined as a 
50% increase in opioid dose in the first 3 months of treatment, or 100% increase 
in dose during the 12-month post-period. Groups were compared on the patient 
characteristics of age, gender, Charlson Comorbidity, and region of residence, 
and on the change in health care service utilization and expenditure over an 18-
month period. RESULTS: Members in the Doctor Shopping group were 
significantly more likely to be female than members in the Rapid Dose Escalation 
group (57.1% vs. 51.3%; p < .025), and also incurred significantly greater increases 
in emergency room charges ($810 vs. $265; p < 0.005). The two groups did not 
differ on any remaining demographics or service utilization estimates, including 
inpatient admissions, days, and costs; office visits and costs; outpatient hospital 
visits and costs; total prescription and opioid-specific costs and days’ supply; 
total health care costs; and the Charlson (p’s > 05). CONCLUSIONS: Results 
revealed only slight differences in demographic makeup and health care 
expenditure across the two problematic opioid use groups, suggesting the 
successful identification of a single, homogenous group. The use of either 
method alone would likely underestimate the prevalence of this burgeoning 
problem.  
PRM3  
THE EFFECT OF REDESIGNED COMPUTERIZED DRUG-DRUG INTERACTION 
ALERTS ON MEDICATION ERRORS AND PRESCRIBING EFFICIENCY  
Chen S1, Zillich AJ1, Melton BL2, Saleem JJ1, Johnson E2, Weiner M1, Russell SA1, McManus 
MS1, Doebbeling BN1, Russ AL1 
1Richard L. Roudebush VA Medical Center, Indianapolis, IN, USA, 2Purdue University, West 
Lafayette, IN, USA  
OBJECTIVES: Computerized medication alerts, such as drug-drug interaction 
(DDI) warnings, are intended to improve decision-making at the time of 
prescribing and enhance patient safety. The alert interface influences 
prescribers’ perceptions of warnings, but the interface design of DDI alerts is 
largely unstudied. The objectives were to conduct a simulation study to evaluate 
whether design changes reduce medication errors and improve prescribing 
efficiency. METHODS: We conducted a counterbalanced crossover study with 
outpatient prescribers to evaluate two different DDI alert designs. Redesigned 
alerts incorporated human factors principles such as guidelines for warning 
design; the original alert design served as the control. During the simulation, 
Veterans Affairs outpatient prescribers completed three fictional patient cases 
using both the original and the redesigned alerts. We used six clinically relevant 
DDI alerts of varying severity. Prior to data collection, each DDI was assigned 
correct and incorrect actions to evaluate medication errors. The primary 
outcome was medication errors defined as the number of incorrect actions over 
the number of alerts prescribers received. A secondary outcome was prescribing 
efficiency, defined as the time spent reviewing and resolving all alerts within 
one patient case. The original and redesigned alerts were compared using 
McNemar’s test for medication errors and Wilcoxon signed-rank test for 
efficiency. RESULTS: Twenty prescribers (14 physicians, 4 pharmacists, and 2 
nurse practitioners) completed patient cases for both designs. Medication errors 
were significantly reduced with redesigned alerts (27.5%) compared to the 
original alerts (47.4%; p<0.001). Median time spent on redesigned alerts was 52 
seconds compared to 97 seconds for the original alerts (p<0.001), saving 
prescribers 45 seconds per case. CONCLUSIONS: Based on this simulation study, 
incorporating human factor principles into computerized medication alert 
systems may improve prescribing and patient safety. Evaluation of redesigned 
alerts in a clinical setting is needed to understand the effects during actual 
patient care.  
 
PRM4  
TO STUDY THE OUTCOME OF HOSPITALIZATION IN ISCHEMIC VERSUS 
HEMORRHAGIC STROKE  
Gupta SK1, Sharma K2, Mukherjee JD3 
1DIPSAR, University of Delhi, NEW DELHI, India, 2DIPSAR, NEW DELHI, India, 3Max Super 
specialty hospital, New Delhi, India  
OBJECTIVES: To assess and compare the functional outcome/recovery of ischemic 
and intracerebral hemorrhage at discharge from hospital, using modified rankin 
scale and barthel index. METHODS: In the present retrospective study, 140 stroke 
patients (110 patients of infarction including patients of Transient Ischemic Attack 
and 30 hemorrhage patients) were enrolled, their medical records studied and were 
compared for risk factors, disability at discharge, groups’ length of stay and 
mortality. Mean scores on both, Modified Rankin Scale (mRS) and Barthel Index (BI) 
were determined at admission and discharge and then compared using paired ttest. 
Ischemic group was also sub-divided into 2 groups on the basis of treatment with 
tissue plasminogen activator (t-PA) and their scores were also compared with same 
test. Good (mRS score <2 and BI score > 60) or poor outcome (mRS score >2 and BI 
score < 60), were distinguished in both the stroke groups using on both scales. 
RESULTS: Ischemic stroke patients had higher mean score on Barthel Index (70.2, 
p=0.0026) and lower mean score on Modified Rankin Scale (2.3, p=0.000) at discharge 
compared to hemorrhage patients (BI score = 36.67 and mRS score = 3.7). 
Hypertension was determined as the most prevalent risk factor in both the stroke 
types. CAD, atrial fibrillation, previous stroke, diabetes mellitus, alcohol were other 
major factors. ~65% ischemic stroke patients were discharged with a good outcome 
whereas only 30% patients in the hemorrhage group were discharged with a good 
outcome. Patients treated with t-PA experienced better outcome than the patients 
managed conservatively. CONCLUSIONS: The results provide evidence of better 
functional outcome and recovery in ischemic stroke patients at discharge and 
greater risk of mortality in patients with intracerebral hemorrhage.  
 
PRM5  
COMPOSITE ENDPOINTS IN TREATMENT OF TYPE-2 DIABETES  
Einarson TR1, Hemels M2 
1University of Toronto, Toronto, ON, Canada, 2Janssen Cilag, Birkerød, Denmark  
OBJECTIVES: Composite endpoints (CEPs) are being used more frequently in 
describing outcomes for trials of drugs in type-2 diabetes. We reviewed the 
literature on CEPs to determine how they have been used to date on currently 
marketed antidiabetics. METHODS: Medline, Embase and Cochrane databases 
and Clinicaltrials.gov were searched for randomized controlled Phase-3 trials of 
currently marketed incretins, which were grouped by class. We sought trials of 
GLP-1 agonists, DPP-4 inhibitors and SGLT-2 inhibitors. CEPs used were identified 
as well as numbers and percentages of patients achieving each, the time of 
measuring the CEPs and the comparison drugs involved in those trials. RESULTS: 
Twelve studies involving 5611 patients provided data. Drug classes included GLP-
1 agonists (exenatide 10 mcg twice daily, exenatide 2 mg weekly, liraglutide 1.2 
mg daily, and liraglutide 1.8 mg daily), DPP-4 inhibitors (sitagliptin 100 mg daily). 
No studies were found in the literature reporting CEPs for SGLT-2 inhibitors. 
Approximately 18% of patients were treated as first line therapy, 55% as second 
line, and 27% as third. Active comparison drugs and background treatments 
included insulin, metformin, sulfonyluyreas, and thiazolidinediones. Eleven 
different CEPs were used (6 with 2 components, 5 with 3 components). All CEPs 
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incorporated HbA1c<7% at endpoint, reflecting ADA recommendations; others 
included no weight gain (NWG), no hypoglycemia (NH), SBP<130, and LDL<2.6. 
The averge proportion achieving 2-component CEPs at 26 weeks was 36% 
(median=35%); an average of 17% (median=13%) achieved 3-component CEPs. 
One 3-component CEP (HbA1c+NWG+NH) had rates for both 26 and 52 weeks. 
The proportion achieving this CEP increased 23% between weeks 26 and 52. 
Proportions meeting CEPs increased by 67%-150% in patients with baseline 
HbA1c levels >8.0%. CONCLUSIONS: CEPs have been used to a limited extent as 
indicators of clinical outcomes in type-2 diabetes trials. More research is 
required to identify optimal CEPs.  
 
PRM6  
MEDICATION ADHERENCE FOR CLOZAPINE VERSUS OTHER SECOND-
GENERATION ANTIPSYCHOTIC DRUGS IN PATIENTS WITH SCHIZOPHRENIA  
Velligan DI1, Carroll CA2, Lage MJ3 
1University of Texas Health Sciences Center San Antonio, San Antonio, TX, USA, 2Teva 
Pharmaceuticals, Kansas City, MO, USA, 3HealthMetrics Outcomes Research, Delray Beach, FL, 
USA  
OBJECTIVES: To compare adherence rates and health care utilization for 
clozapine versus other second-generation antipsychotics used as monotherapy 
in the treatment of schizophrenia. METHODS: The study was an observational, 
retrospective analysis of medical and pharmacy claims from a national 
insurance organization with approximately 14 million enrollees, conducted using 
the i3 InvisionTM Data Mart database for dates of service from January 2006 
through December 2009. Study patients had >1 pharmacy claim for a second-
generation antipsychotic (study drugs: apiprazole, clozapine, olanzapine, 
paliperidone, quetiapine, risperidone, or ziprasidone) with no pharmacy claims 
for any study drug during a 6-month preperiod prior to the initial (index) claim. 
All patients met the following criteria: no pharmacy claims for any second-
generation antipsychotic other than the index medication during the 90 days 
following the index claim; aged 18 to 64 years; continuously enrolled from the 
preperiod through 12 months after the index date (postperiod); and >1 medical 
claim with a diagnosis of schizophrenic disorder (ICD-9-CM=295.xx) in either 
period. Logistic regression analyses modeled binomial measures of postperiod 
medication possession ratio (MPR) for the index drug (>80%=adherent) and 
postperiod hospitalizations and emergency room (ER) use in 3 categories: all-
cause, mental disorder-related (ICD-9-CM=290.xx-319.xx), and schizophrenia 
related (ICD-9-CM=295.xx), controlling for patient demographics, preperiod 
hospitalization and ER use, and preperiod comorbidities. RESULTS: Mean MPRs 
for the sample (N=19,804) were 0.78 for clozapine, 0.62 for quetiapine, and 0.42-
0.49 for the remaining study drugs. In logistic regression analyses, the odds of 
MPR >80% were lower for all study drugs compared with clozapine (odds ratio 
[OR]=0.603, 95% confidence interval=0.483-0.754 for quetiapine and ORs=0.306 to 
0.390 for remaining drugs). CONCLUSIONS: Compared with other second-
generation antipsychotics, treatment with clozapine is associated with better 
adherence and equal or less all-cause and disease-specific hospital care 
utilization. These findings should be interpreted in light of the benefits and risks 
of all antipsychotic drugs.  
 
PRM7  
WHY ARE THE FINDINGS OF INDIRECT COMPARISONS OF BOCEPREVIR AND 
TELAPREVIR FOR HEPATITIS C INFECTION DIFFERENT? A METHODOLOGICAL 
REVIEW  
Druyts E1, Thorlund K2, O'Regan C3, Mills E4 
1University of Ottawa, Ottawa, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 
3Merck Sharp and Dohme Ltd, UK, 4Stanford University, Palo Alto, CA, USA  
OBJECTIVES: To evaluate the methods and results of published indirect 
comparison meta-analyses of boceprevir and telaprevir for genotype 1 hepatitis 
C infection, and to identify methodological issues that can explain the 
discrepancies in the results of these meta-analyses. METHODS: We searched 
MEDLINE and EMBASE for indirect comparisons of boceprevir and telaprevier for 
genotype 1 hepatitis C infection. Following the PRISMA guidelines, we extracted 
a large set of methodological items. These comprised of inclusion/exclusion 
criteria, information sources, classification of treatments, and analytic 
approaches. RESULTS: We identified 4 indirect comparisons. Despite similarly 
stated eligibility criteria and objectives across these indirect comparisons, we 
identified discrepancies in the selection of pooled arms and the analytic 
approaches used, which are most likely to have influenced the differences in the 
estimated treatment effects. While three of the four studies stratified their 
analyses by standard-duration therapy (SDT) arms and response-guided therapy 
(RGT) arms of comparable dose and length of treatment, one study pooled both 
SDT and RCT therapy together. Three of the four studies used a Bayseian 
approach, and one used an adjusted Bucher approach. The use of random and 
fixed effects models also differed between the studies. Furthermore, the type of 
peg-interferon used (alpha-2a versus alpha-2b) was only given full consideration 
in 2 of the included studies. Finally, although no study observed statistical 
differences between boceprevir and telaprevir, the estimated treatment effects 
differed. CONCLUSIONS: The identified methodological shortcomings and 
inconsistencies most likely explain the observed discrepancies in findings 
between the indirect comparisons. Consideration of the methodological 
differences is necessary when interpreting the results of these studies.  
 
PRM8  
ESTIMATION OF LONG-TERM CARE NEEDS IN PATIENTS UNDER 
MAINTENANCE HEMODIALYSIS  
Hung MC1, Wang JD2 
1Department of Public Health, National Cheng Kung University Medical College, Tainan, Taiwan, 
2National Cheng Kung University College of Medicine, Tainan, Taiwan  
OBJECTIVES: The long-term care needs in patients under maintenance 
hemodialysis (HD) have not been explored before. To estimate the changes of 
proportion for different functional disabilities along time after beginning HD and 
the lifelong care needs. METHODS: We used a population-based cohort 
consisting of 84,657 incident patients under maintenance HD in Taiwan between 
1998 and 2009 to calculate the survival functions. The Barthel Index (BI) was used 
to measure functional disability levels cross-sectionally in 1272 HD patients 
recruited from multiple HD centers. A BI score less than 50 was considered a 
severe disability. The kernel-smoothing method was used to estimate the 
dynamic changes of different functional disability. The survival function was 
extrapolated to lifetime by a semi-parametric method and then multiplied with 
proportions of different kinds of functional disabilities over time to obtain the 
lifetime care needs after age stratification. RESULTS: On average, patients under 
maintenance HD had 6.5 (± 0.1) years without disability, 1.9 (± 0.1) years with 
moderate disability, and 1.3 (± 0.1) years with severe disability. The most 
common needs for assistance throughout their lifetimes were stair-climbing and 
bathing which were 2.8 years and 1.6 years, respectively. HD patients were 
expected to have about 3 years living with disabilities for all age groups above 35; 
however, old patients showed higher proportions of functional disabilities. 
CONCLUSIONS: HD patients are in need of long term care. The older the age, the 
higher the proportions that need different care services.  
 
PRM9  
COMPARISON OF TRADITIONAL STATIN ADHERENCE MEASUREMENT WITH 
AN ENHANCED METHOD ALLOWING FOR MORE INCLUSIVE PATIENT 
MEASUREMENT  
Jiang JZ, Taitel M, Rudkin K, Fensterheim L 
Walgreen Co., Deerfield, IL, USA  
OBJECTIVES: The methodology used to estimate medication adherence typically 
identifies patients with sold scripts during a specified index period. We propose 
a new method for calculating medication adherence that expands the patient 
population by including patients who filled medications and those who did not 
fill medication, but were expected to fill or had available medication during the 
index period. METHODS: During the index period of January 2011, patients 
filling, expected to fill, or who had statin medication on hand from a national 
retail pharmacy were included in the study. 12-month adherence metrics were 
calculated using the traditional method as well as the enhanced method using 
proportion of days covered (PDC). Patients were also segmented by refill 
behaviors such as new, returning, late, and continuing therapy and expected 
non-fillers. RESULTS: We identified 2,278,751 statin patients using the traditional 
method. The enhanced method identified 556,525 additional expected non-filler 
patients and 815,775 patients with available medication. Of the additional 
patients from the enhanced method, 67% eventually refilled their prescriptions 
in the subsequent 2 months. The enhanced method had an overall 12-month 
adherence of 0.693 compared to 0.733 for the traditional method. PDCs ranged 
from (0.420 - 0.794) depending on patient segment. These results are from a 
single pharmacy chain. Patients switching pharmacies will not be fully captured 
in these results. CONCLUSIONS: This enhanced method for measuring 
adherence identifies a more complete patient population of those at risk for 
hyperlipidemia because it accounts for all patients during the index period. 
Although the additional patients could be included using the traditional method 
within a 3-month index period, the new method captures all patients who are on 
therapy during a shorter index period. This enhanced method allows for quicker 
analysis to support interventions that improve patient’s adherence.  
 
PRM10  
EXPLORATION OF HETEROGENEITY IN DISTRIBUTED RESEARCH NETWORK 
DRUG SAFETY ANALYSES  
Hansen RA1, Zeng P1, Ryan PB2, Gao J1, Sonawane K1, Dubois RW3, Westrich KD3 
1Auburn University, Auburn, AL, USA, 2Janssen Research and Development, Titusville, NJ, USA, 
3National Pharmaceutical Council, Washington, DC, USA  
OBJECTIVES: Distributed data networks are an expanding focus of drug safety 
research. However, interpreting results of distributed analyses is challenging 
when treatment effects are heterogeneous. We assessed heterogeneity of 
treatment effects and explored factors influencing heterogeneity using 
experimental results from the Observational Medical Outcomes Partnership 
(OMOP). METHODS: OMOP evaluated risk of eight health outcomes across nine 
drug groups, replicating analyses across eight data sources using a common data 
model. We focused on the OMOP propensity score analyses and assessed 
heterogeneity using meta-analysis and I-squared statistics. Plots of the 
relationship between influence on overall results and contribution to overall 
heterogeneity identified influential data sources. Summary-level data source 
characteristics were examined to identify potential factors with high variability 
that could be influencing results. Exploratory meta-regression further assessed 
the relationship of summary-level characteristics with heterogeneity using risk 
of bleeding with warfarin and un-related negative controls (antibiotics, 
benzodiazepines, and tricyclic antidepressants). RESULTS: Heterogeneity, as 
measured by the I-squared statistic, ranged from 0-99% across the drug-outcome 
pairs studied. In general, heterogeneity generally was lower for analyses of 
angioedema (0-71%) and aplastic anemia (0-84%) and higher for acute liver injury 
(74-91%) and bleeding (78-99%). Plots of the relationship between influence on 
overall results and contribution to heterogeneity illustrated limited data source 
clustering, which is an indicator that heterogeneity was not driven by a single 
dataset but rather was unique to the drug and outcome being assessed. 
Exploratory meta-regression identified many variables influencing 
heterogeneity, but was unable to accurately identify specific factors that were 
most influential. CONCLUSIONS: Distributed data network drug safety analyses 
are challenging to interpret in the face of heterogeneity. A formal assessment of 
